The First Gene Therapy JCA: Absence of Evidence Versus Evidence of Absence
Gene therapy JCA submissions face a distinct methodological test, and the first assessment under the EU…
Category Blogs
Can We Predict Pricing Potential Before Launch? Putting GPI Horizon to the Test
Pre-launch price forecasting for rare disease assets was tested against two named products in 2024. GPI…
How should you evaluate a pharmaceutical pricing data provider?
Evaluate a pharmaceutical pricing data provider on the questions your team already asks, not on a…
Two Small-Cell Lung Cancer Drugs, Two JCAs, Two Very Different Evidence Stories
Joint Clinical Assessment evidence requirements have been tested twice in recent months, through the JCA reports…
The First EU Joint Clinical Assessment Wasn’t About Ojemda. It Was About Comparative Evidence.
The EU Joint Clinical Assessment process produced its first completed output in June 2026, with the…
From Cost Pressure to Strategic Opportunity: The Transformation of NHS Medicines Expenditure
NHS medicines expenditure grew 51.9% between 2019/20 and 2024/25, and the policy environment shaping that spend…
GLP-1s have forced pharma to take D2C seriously. Is your strategy keeping pace?
Pharma D2C strategy is no longer a fringe consideration. As reimbursement constraints limit patient access to…
Evidence, Uncertainty, and Added Benefit: What 198 Orphan Drug Assessments Reveal About HTA Outcomes in Germany
G-BA added benefit determinations shape reimbursement and market access outcomes for orphan therapies in Germany, yet…
Beyond Clinical Evidence: Value Differentiation in Breast Cancer Market Access
Oncology market access strategy depends on more than clinical evidence alone. This analysis examines how value…
